Literature DB >> 3107848

Interferon-gamma and cytotoxic agents studied in combination using a soft agarose human tumor clonogenic assay.

T Saito, M E Berens, C E Welander.   

Abstract

The in vitro antiproliferative activity of human recombinant interferon-gamma (IFN-gamma) was tested against human tumor cells in vitro in combination with doxorubicin, cisplatin, or vinblastine. Using a human tumor clonogenic assay (HTCA), IFN-gamma alone showed dose-dependent inhibition of colony growth in six or seven human tumor cell lines as well as in each of nine fresh ovarian tumor specimens. The combination of IFN-gamma and either doxorubicin or cisplatin showed additive antiproliferative effects against all the cell lines with the exception of an IFN-gamma-resistant endometrial cancer cell line (HEC-1A). In combination with vinblastine, IFN-gamma rarely had an additive effect. Inclusion of macrophages from malignant effusions in the HTCA potentiated the antiproliferative effect of IFN-gamma alone as well as the combination of IFN-gamma and doxorubicin; however, the efficacy of the two agents was never more than additive. The results show that combinations of IFN-gamma with doxorubicin or cisplatin are additive and warrant further investigation. The antitumor effect of IFN-gamma alone or in combination with cytotoxic drugs may be significantly enhanced by tumor-associated macrophages.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3107848     DOI: 10.1007/bf00252978

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  36 in total

1.  Synergistic interaction of anticancer agents: a cellular perspective.

Authors:  F Valeriote; H s Lin
Journal:  Cancer Chemother Rep       Date:  1975 Sep-Oct

2.  Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma.

Authors:  Y Matsuoka; G E Moore; Y Yagi; D Pressman
Journal:  Proc Soc Exp Biol Med       Date:  1967 Aug-Sep

3.  Use of an image analysis system to count colonies in stem cell assays of human tumors.

Authors:  B E Kressner; R R Morton; A E Martens; S E Salmon; D D Von Hoff; B Soehnlen
Journal:  Prog Clin Biol Res       Date:  1980

4.  Rationale for the use of alternating non-cross-resistant chemotherapy.

Authors:  J H Goldie; A J Coldman; G A Gudauskas
Journal:  Cancer Treat Rep       Date:  1982-03

5.  A preliminary Phase I trial of partially purified interferon-gamma in patients with cancer.

Authors:  S A Sherwin; K A Foon; P G Abrams; M R Heyman; J J Ochs; T Watson; A Maluish; R K Oldham
Journal:  J Biol Response Mod       Date:  1984-12

6.  Recombinant human gamma-interferon in primary hepatocellular carcinoma.

Authors:  A Forbes; P J Johnson; R Williams
Journal:  J R Soc Med       Date:  1985-10       Impact factor: 5.344

7.  Combined recombinant human interferon alpha 2 and cytotoxic agents studied in a clonogenic assay.

Authors:  C E Welander; T M Morgan; H D Homesley; P P Trotta; R J Spiegel
Journal:  Int J Cancer       Date:  1985-06-15       Impact factor: 7.396

8.  Potentiation of the direct anticellular activity of mouse interferons: mutual synergism and interferon concentration dependence.

Authors:  W R Fleischmann
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

9.  Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients.

Authors:  R Kurzrock; M G Rosenblum; S A Sherwin; A Rios; M Talpaz; J R Quesada; J U Gutterman
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

10.  Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing.

Authors:  J L Pace; S W Russell; B A Torres; H M Johnson; P W Gray
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

View more
  2 in total

Review 1.  Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis.

Authors:  D J Stewart; G P Raaphorst; J Yau; A R Beaubien
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

2.  Combinations of interferon with platinum complexes: synergistic and antagonistic effects on growth inhibition of MCF-7 and MDA-MB231 breast cancer cells.

Authors:  A M Otto
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.